Ask AI
ProCE Banner Activity

Maximizing Patient Benefit With Adjuvant CDK4/6 Inhibitors for High-Risk HR+/HER2- Early Breast Cancer

Slideset

Download this slideset from a live series on multidisciplinary care of patients with high-risk HR-positive/HER2-negative early-stage breast cancer, including patient selection for adjuvant CDK4/6 inhibitors, toxicity management, and adherence considerations.

Released: August 28, 2025

Share

Provided by

Provided by Clinical Care Options, LLC. in partnership with Smart Patients.

ProCE Banner

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation

Partners

Smart Patients

ProCE Banner